Hypoplasia

Medical Solutions Grants Teen's Wish Through Make-A-Wish Foundation

Retrieved on: 
Tuesday, May 9, 2023
Volunteering, Heart, Partnership, Pregnancy, Travel, Hypoplastic left heart syndrome, Parent, Rising Medical Solutions, Eye, Congenital heart defect, Make-A-Wish Foundation, Sibling, Health, Family, Hypoplasia, Dentistry, Residential care, Toy

Thanks to Medical Solutions' partnership with the Make-A-Wish Foundation, Brady will fulfill his wish of traveling to Hawaii with his family.

Key Points: 
  • Thanks to Medical Solutions' partnership with the Make-A-Wish Foundation, Brady will fulfill his wish of traveling to Hawaii with his family.
  • He and his mom, Lisa, joined Medical Solutions on Thursday, April 27, for a special company event, where the wish was announced to its nearly 2,800 corporate employees.
  • The presentation featured remarks by Medical Solutions CEO Craig Meier and Brigette Young, Make-A-Wish Nebraska president.
  • Make-A-Wish Nebraska President Young thanked Medical Solutions for granting Brady's wish, and for the company's continued support of the organization.

Longeveron Announces First Patient Treated in Phase 2b Hypoplastic Left Heart Syndrome (HLHS) Clinical Study

Retrieved on: 
Tuesday, July 6, 2021
Congenital heart defects, Medical specialties, Branches of biology, Medicine, HLHS, Hypoplastic left heart syndrome, Hypoplasia, Acute respiratory distress syndrome

Lomecel-B is an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product manufactured in Longeverons cell processing facility in Miami, Florida.

Key Points: 
  • Lomecel-B is an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product manufactured in Longeverons cell processing facility in Miami, Florida.
  • Longeveron s HLHS program has transitioned to Phase 2, with a randomized, double-blind, controlled trial titled: Evaluation of Lomecel-B Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial.
  • HLHS is a rare congenital heart defect that effects approximately 1,000 babies per year in the U.S.
  • Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).

Longeveron Invited to Present at the Benzinga Global Small Cap Conference

Retrieved on: 
Wednesday, May 5, 2021
Branches of biology, Biology, Stem cells, Life sciences, Biotechnology, Cell biology, Cell therapy, HLHS, Hypoplastic left heart syndrome, Mesenchymal stem cell, Hypoplasia

The Company\xe2\x80\x99s lead investigational product is the LOMECEL-B\xe2\x84\xa2 cell-based therapy product (\xe2\x80\x9cLomecel-B\xe2\x80\x9d), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors.

Key Points: 
  • The Company\xe2\x80\x99s lead investigational product is the LOMECEL-B\xe2\x84\xa2 cell-based therapy product (\xe2\x80\x9cLomecel-B\xe2\x80\x9d), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors.
  • Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders.
  • Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer\xe2\x80\x99s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
  • Further information relating to factors that may impact the Company\'s results and forward-looking statements are disclosed in the Company\'s filings with the SEC.

Global Fanconi Anemia (FA) Pipeline Insights 2019 - Treatment Patterns, Analytical Perspective, Pipeline Therapeutics, Products Analysis, Recent Technologies, Key Companies

Retrieved on: 
Friday, October 18, 2019
Medical specialties, Branches of biology, Medicine, Fanconi anemia, Hematopathology, Fanconi, Hypoplasia, Anemia, Fanconi syndrome

Fanconi Anemia (FA) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.

Key Points: 
  • Fanconi Anemia (FA) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Fanconi Anemia pipeline landscape is provided which includes the disease overview and Fanconi Anemia treatment guidelines.
  • The assessment part of the report embraces, in depth Fanconi Anemia commercial assessment and clinical assessment of the pipeline products under development.
  • Fanconi Anemia (Fanconi hypoplastic anemia, Fanconi pancytopenia, Fanconi panmyelopathy)

Fanconi Anemia (FA) Pipeline Insight, 2019 Report - ResearchAndMarkets.com

Retrieved on: 
Friday, October 18, 2019
Health, Pharmaceutical, Medical specialties, Branches of biology, Medicine, Fanconi anemia, Hematopathology, Fanconi, Hypoplasia, Anemia, Fanconi syndrome

Fanconi Anemia (FA) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.

Key Points: 
  • Fanconi Anemia (FA) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Fanconi Anemia pipeline landscape is provided which includes the disease overview and Fanconi Anemia treatment guidelines.
  • The assessment part of the report embraces, in depth Fanconi Anemia commercial assessment and clinical assessment of the pipeline products under development.
  • Fanconi Anemia (Fanconi hypoplastic anemia, Fanconi pancytopenia, Fanconi panmyelopathy)